Goldman Sachs raises Nuvalent stock price target to $135 on positive cancer drug data
PositiveFinancial Markets

- Goldman Sachs has increased the stock price target for Nuvalent to $135 based on encouraging data from its cancer drug trials, signaling strong confidence in the company's future performance. This adjustment comes as Nuvalent progresses in its clinical developments, which are critical for its market positioning.
- This development is significant as it highlights the potential for Nuvalent to attract more investors and enhance its market presence in the competitive oncology sector. A higher price target may lead to increased investor interest and could positively impact the company's stock performance.
— via World Pulse Now AI Editorial System






